Awaiting IPO, CardioDx Q3 Revenues up Sharply | GenomeWeb

NEW YORK (GenomeWeb News) – Cardiovascular molecular diagnostics firm CardioDx, which plans to go public with an intended offering of up to $86.3 million, said that its revenues for the first nine months of the year shot up more than five-fold year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.